

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A pharmaceutical Pharmaceutical preparation that contains comprising:

(a) at least one an emulsifier that is PEG-40-hydrogenated castor oil (Cremophor®RH40), PEG-35 castor oil (Cremophor®EL) or PEG-400-monoricin oleate (Estax®54),

(b) at least one an auxiliary emulsifier and/or solvent that is glyceryl monocaprylate > 80% (m/m) (Imwitor®308) or diethylene glycol monoethyl ether (Transcuto1®P) and

(c) as well as and at least one a lipid that is a mid-chain triglyceride, fatty oil or wax,

characterized in that wherein the mass ratio of emulsifier to auxiliary emulsifier and/or solvent (Smix) is 1:1 to 9:1 and the total lipid proportion is > 10-50 % (m/m), whereby this preparation at least partially inhibits at least one intestinal enzyme and/or at least one intestinal efflux system.

2. (Currently Amended) Pharmaceutical-A pharmaceutical preparation according to claim 1, wherein the Smix is 3:1 to 9:1.

3. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to claim 3, wherein the Smix is 9:1.

4. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to Claim 1, ~~wherein the total lipid proportion-the preparation contains 10-50% (m/v) a steroid.~~

5-8 (Cancel)

9. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to claim 8, wherein the triglyceride contains mid-chain triglycerides (Miglyol[®]).

10. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to claim 8, wherein the fatty oil ~~contains~~ comprises castor oil, olive oil, corn oil, soybean oil, sunflower oil, peanut oil, walnut oil or diestel oil.

11. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to claim 8, wherein the wax ~~contains~~ comprises ethyl oleate or isopropyl myristate.

12-18 (Cancel)

19. (Currently Amended) Pharmaceutical A pharmaceutical preparation according to claim 18, wherein the steroid in 17-position of the sterane skeleton contains a secondary, beta-position hydroxyl group.

20. (Currently Amended) Pharmaceutical A pharmaceutical preparation according to Claim 1, wherein the steroid is an estrogen, an antiestrogen or an androgen.

21.(Currently Amended) Pharmaceutical A pharmaceutical preparation according to Claim 1, wherein the steroid is 11- α -hydroxynandrolone, 16- α -fluoroestradiol, 16- α -idoestradiol, 16- β -fluoroestradiol, 2,4-dibromoestradiol, 2-chloroestradiol, 2-ethoxyestradiol, 2-fluoroestradiol, 2-hydroxyestriol, 2-methoxyestradiol, 2-methoxyestriol, 2-methoxymethylestradiol, 3-methoxyestriol, 4-bromoestradiol, 4-chloroestradiol, 4-fluoro-17 β -estradiol, 4-hydroxyestradiol, 4-hydroxytestosterone, 4-methoxyestradiol, 5- β -androstan-17 β -ol-3-one, 6- α -hydroxyestradiol, 3 α , 17 β -androstanediol, 3 β ,17 β -androstanediol, androstanolone, androstenediol, bolanediol, bolazine, boldenone, clostebol, dacuronium bromide, 17-deacetylpancuronium, dideactetylvecuronium, vecuronium, 17 β -dihydroequilin, 5 α -dihydro-19-nortestosterone, 16 α -bromo-7 α -(N-butyl, N-methyl-undecanamide)-estra-1,3,5(10)-triene-3,17 β -diol, 16 α -chloro-7 α -(N-butyl, N-methyl-undecanamide)-estra-1,3,5(10)-triene-3,17 β -

diol, 16 α -iodo-7 α -(N-butyl, N-methyl-undecanamide)-estra-1,3,5(10)-triene-3,17 β -diol, 16 α -bromo-7 α -(N-butyl, N-methyl-undecanamide)-estra-1,3,5(10)-triene-3,17 β -diol, epiestriol, epitostanol, estetrol, estradiol, estradiol-3-glucuronide, estradiol-3-methylether, estradiol-3-sulfate, estradiol-3-benzoate, estradiol-3-hexahydrobenzoate, estramustine, estriol, estriol-3-glucuronide, estriol-3-sulfate, estriol-16-glucuronide, estrynamine, 17 β -hydroxy-6-methylene-androsta-1,4-dien-3-one, fulvestrant, 1-hydroxy-17 β -estradiol, 2-hydroxy-17 β -estradiol, 4-hydroxy-17 β -estradiol, 6-hydroxy-17 β -estradiol, 7-hydroxy-17 β -estradiol, 15-hydroxy-17 β -estradiol, 18-hydroxy-17 β -estradiol, 7-(N-butyl-undecanamide)-3,17 β -estra-1,3,5(10)-triene-3,17 β -diol, 7 α -(N-butyl-undecanamide)-3,17 β -estra-1,3,5(10)-triene-3,17 β -diol, 7 α -(N-butyl, N-methyl-undecanamide)-estra-1,3,5(10)-triene-3,17 β -diol, inocoterone, estra-3-sulfamate-1,3,5(10),7-tetraene-3,17 β -diol, cycloprop[14S,15 β]-3',15-dihydro-estra-1,3,5(10)-triene-3,17 β -diol, estra-1,3,5(10)-triene-3-sulfamate-17 β -ol, mesterolone, methenolone, 16-methyleneestradiol, metogest, nandrolone, nisterime, norclostebol, 3-octyloxy-5 α -androst-3-en-17 β -ol, estradiol-17-phenylpropionate-estradiol-benzoate mixture, 7-ethyl-nandrolone, 11 β -chloromethyl-estra-3,17 β -diol, piperidinium-1-[(2 β ,3 α ,5 α ,16 β ,17 β)-3,17-dihydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl-bromide, 17-deacetylrocuronium, oxendolone, 11 α -methoxy-7 α -methyl-estra-3-17 β -diol,

quinestradiol, 17 β -hydroxy-7 α -methyl-androst-5-en-3-one, 11 α -ethenyl-estra-3, 17 β -diol, 11 β -[4(dimethylamino)phenyl]-estra-3, 17 β -diol, 7 α -{4-[2-(dimethylamino)ethoxy]phenyl}-estra-3, 17 β -diol, 11 β -{4-[[(methylsulfonyl)oxy]phenyl]-estra-3, 17 β -diol, 11 β -{4-[[5-[(4,4,5,5,5-pentafluoropentyl)sulfonyl]pentyl]oxy]phenyl}-estra-3, 17 β -diol, 17 β -dihydroxy-9 α -fluoro-11 β -androsta-1,4-dien-3-one, stenbolone, cycloprop[14R,15 α]estra-3', 15-dihydro-3-methoxy-1,3,5(10)-trien-17 β -ol, cycloprop[14S,15 β]estra-3', 15-dihydro-3-methoxy-1,3,5(10)-trien-17 β -ol, testosterone, trestolone, trilostane, 13 β -ethyl-8 α -gona-1,3,5(10)-triene-3, 16 α , 17 β -triol, 13 β -ethyl-8 β -gona-1,3,5(10)-triene-3, 16 α , 17 β -triol, estra-2-{tricyclo[3.3.1.13,7]decyl}-1,3,5(10)-triene-3, 17 β -diol, ent-estradiol, 8 β -vinyl-estradiol, 11 β -fluoro-7 α -{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)-propylamino]pentyl}-estra-1,3,5(10)-triene-3, 17 β -diol, 11 β -fluoro-7 α -{5-[methyl-(7,7,8,8,9,9,10,10,10-nonafluorodecyl)amino]pentyl}-estra-1,3,5(10)-triene-3, 17 β -diol, 11 β -fluoro-17 α -methyl-7 α -{5-[methyl-(8,8,9,9,9-pentafluorononyl)amino]-pentyl}-estra-1,3,5(10)-triene-3, 17 β -diol, 17 β -hydroxy-14 α , 15 α -methylene-androst-4-en-3-one, 4-chloro-17 β -hydroxy-14 α , 15 α -methylene-androst-4-en-3-one, 4, 17 β -dihydroxy-14 α , 15 α -methylene-androst-4-en-3-one, 17 β -hydroxy-14 α , 15 α -methylene-androsta-1,4-dien-3-one, 4-chloro-17 β -hydroxy-14 α , 15 α -

methylene-androsta-1,4-dien-3-one, 4-chloro-17 β -hydroxy-14 α ,15 α -methylene-estr-4-en-3-one, 7 β -hydroxy-7 α -methyl-14 α ,15 α -methylene-estr-4-en-3-one, 17 β -hydroxy-14 α ,15 α -methylene-estr-4-en-3-one, 4,17 β -dihydroxy-14 α ,15 α -methylene-estr-4-en-3-one, 17 β -hydroxy-14 α ,15 α -methylene-estra-4,9,11-trien-3-one, 3-ethyl-17 β -hydroxy-14 α ,15 α -methylene-gon-4-en-3-one, 17 α - β -hydroxy-17 α -homoandrosta-4,15-dien-3-one, 1''-mesyl-17 α -(trifluoromethyl)-1'H-pyrazol[4'',5':2,3]androst-4-en-17 β -ol.

22. (Currently Amended) ~~Use of a pharmaceutical preparation according to Claim 1, for the production of a peroral pharmaceutical agent~~ A method for inhibiting at least one intestinal enzyme and/or at least one intestinal efflux system comprising administering a pharmaceutical preparation according to Claim 1, to a patient in need thereof.

23. (Currently amended) ~~Use of a pharmaceutical preparation~~ A method according to claim 22, wherein at least one intestinal enzyme originates from the group of 17 β -hydroxy-steroid-dehydrogenases and/or cytochrome-P450-monooxygenases.

24. (Currently amended) ~~Use of a pharmaceutical preparation~~ A method according to claim 23, wherein at least one ~~the~~ intestinal enzyme is 17 β -HSD 2 and/or originates from the group of cytochrome-P450-3A-monooxygenases.

25. (Currently amended) Use of a pharmaceutical preparation A method

according to claim 22, wherein at least one intestinal efflux system is a P-gp-transporter.

26-27 (Cancel)

28. (New) A pharmaceutical composition according to claim 1, comprising

- a) 3,6 g Cremophor®EL, 400 mg Transcutol®P, 1,0 g Miglyol® 812 or
- b) 3,6 g Cremophor®EL, 400 mg Imwitor® 308, 1,0 g Miglyol® 812 or
- c) 3,6 g Cremophor®RH, 400 mg Transcutol®P, 1,0 g Miglyol® 812 or
- d) 3,6 g Estax® 54, 400 mg Transcutol®P, 1,0 g Miglyol® 812 or
- e) 3,6 g Estax® 54, 400 mg Imwitor® 308, 1,0 g Miglyol® 812 or
- f) 3,6 g Estax® 54, 400 mg Transcutol®P, 1,0 g refined castor oil or
- g) 3,6 g Estax® 54, 400 mg Transcutol®P, 1,0 g Ethyloleat or
- h) 3,6 g Estax® 54, 400 mg Polyethylenglykol, 1,0 g Miglyol® 812 or
- i) 3,6 g Cremophor®RH, 400 mg Transcutol®P, 1,0 g refined castor oil or
- j) 3,6 g Cremophor®RH, 400 mg Transcutol®P, 1,0 g Ethyloleat or
- k) 3,6 g Cremophor®EL, 400 mg Transcutol®P, 1,0 g refined castor oil or
- l) 3,6 g Cremophor®EL, 400 mg Transcutol®P, 1,0 g Ethyloleat or
- m) 3,6 g Cremophor®EL, 400 mg Imwitor® 308, 1,0 g Ethyloleat.

29. (New) A pharmaceutical composition according to claim 9, wherein said steroid is:

- a) 11 β -Fluoro-7 α -{5-[methyl-(7,7,8,8,9,9,10,10,10-nonafluorodecyl)-amino]pentyl}estra-1,3,5(10)-trien-3,17 β -diol,

- b) Estra-1,3,5(10)-trien-3,17 β -diol or
- c) 11 β -Fluoro-7 α -{5-[methyl-(4, 4, 5, 5-pentafluoropenty-9-sulfanyl]-propyl}l)-amino]pentyl} estra-1,3,5(10)-trien-3,17 β -diol.